Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Nichi-Iko Pharmaceutical Co., Ltd./Sagent Pharmaceuticals, Inc. tender offer
| July 10, 2016 • Antitrust Risk-shifting • $736 million |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.